NOVALGEN
NovalGen develops breakthrough bispecific therapies for the immune system to fight cancer.
NOVALGEN
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2019-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.novalgen.com
Total Employee:
11+
Status:
Active
Contact:
44-02071-398639
Email Addresses:
[email protected]
Official Site Inspections
http://www.novalgen.com
- Host name: 104.47.160.14
- IP address: 104.47.160.14
- Location: Amsterdam Netherlands
- Latitude: 52.3534
- Longitude: 4.9087
- Timezone: Europe/Amsterdam
- Postal: 1091
More informations about "NovalGen"
NovalGen – Breakthrough multi-specific antibody therapies
Novalgen is a clinical-stage company, revolutionizing the immunology landscape with its innovative autoregulation technology. Our focus is on the next generation of multi-specific …See details»
Patient organisations — Patients & families - Novalgen
At NovalGen, fostering open dialogue and transparent communication with patient organisations is integral to our commitment to patients and caregivers. Recognising the invaluable insights and perspectives they offer, patient …See details»
Member profile: NovalGen Ltd | BIA - bioindustry.org
NovalGen is a privately held immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer.See details»
Our mission - About us - Novalgen
NovalGen is a patient-focused immunology company with a growing pipeline of unprecedented immunology medicines that enhances patient safety whilst making a major impact in the treatment of autoimmune, oncological, and other …See details»
NovalGen - Crunchbase Company Profile & Funding
NovalGen develops breakthrough bispecific therapies for the immune system to fight cancer.See details»
NovalGen - LinkedIn
NovalGen is focused on the development of cutting-edge, proprietary treatments for patients with hematologic malignancies and solid tumors by developing therapeutics that treat cancer using our...See details»
NovalGen enters strategic partnership with HALIX B.V. - Droege …
Feb 22, 2021 · London, United Kingdom and Leiden, The Netherlands, February 22nd 2021 – NovalGen Ltd. (“NovalGen”), a biopharmaceutical company developing breakthrough cancer …See details»
Novalgen Company Profile 2024: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Novalgen. Use the PitchBook Platform to explore the full profile.See details»
Our history - About us - NovalGen
NovalGen has swiftly emerged as a leader in the immunotherapy space. Our agile approach has led to strategic collaborations with prominent institutions like St. Jude Children’s Research Hospital, MD Anderson, alongside critical …See details»
NovalGen receives CTA approval to start a Phase 1/2 first in ... - UCLB
Apr 7, 2021 · NovalGen is a privately held immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer, with the aim of …See details»
NovalGen enters strategic partnership with HALIX B.V. to …
Feb 22, 2021 · London, United Kingdom and Leiden, The Netherlands, February 22 nd 2021 – NovalGen Ltd. (“NovalGen”), a biopharmaceutical company developing breakthrough cancer …See details»
NovalGen announces compelling data from the Phase 1/2 Study
May 26, 2022 · NovalGen is a privately held clinical stage immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer, …See details»
Community support — About us — Novalgen
Community support. At NovalGen, we seek to make a big difference for our patients, but we are also focusing on important aspects in our day-to-day activities: our employees, our community …See details»
Cancer Research UK and NovalGen collaborate to advance T-cell …
Cancer Research UK, one of the world’s largest funders of cancer research, and NovalGen, a pioneering clinical stage immunology company, have signed an agreement to bring …See details»
NovalGen announces compelling data from the Phase 1/2 Study …
May 26, 2022 · - First clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed / refractory CLL and MCL. - Early data demonstrates promising efficacy …See details»
NovalGen presents data at American Society of Clinical Oncology …
May 20, 2021 · NovalGen is a privately held immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer, with the aim of …See details»
NovalGen enters strategic partnership with HALIX B.V.
London, United Kingdom and Leiden, The Netherlands, February 22nd 2021 – NovalGen Ltd. (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies and …See details»
Our technologies - Novalgen
NovalGen’s proprietary ground-breaking autoregulation technology platform enables the maximum efficacy to be unleashed from a therapy whilst ensuring a manageable safety profile …See details»
NovalGen announces one oral and one poster presentation at the …
Nov 13, 2023 · Pre-clinical data for NVG-222, a first in class half life extended Autoregulated T-cell engager targeting ROR1. “We are pleased to announce our forthcoming oral presentation …See details»
Our values — About us - Novalgen
At NovalGen, we seek to make a big difference for our patients, our employees, our community and our environment. Read moreSee details»